We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
ByRuby is a food delivery company. It sources produce from local ethical suppliers, prepares meals in small batches using the raw produce, freezes the meal to preserve the taste, and delivers it nationwide. ByRuby argues that the UK ready meal sales market is worth £12 billion in 2020. The company witnessed sales up to 200% online in March 2020. ByRuby asserts that it uses only British free-range or organic meat & sustainably sourced fish from British waters. The company won the 2018 Women's Health Food Award. Its products are stocked in 26 retail stores. ByRuby has been mentioned by publications such as Daily Mail, Daily Telegraph, and Metro. It will use 50% of the investment for marketing, 26% to grow its kitchen team, 17% to upgrade its kitchen and 7% for new product development.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £288,243
Sendit.Money is a remittance entity. It argues that individuals sending or receiving money in emerging markets can face insecure processes, slow transaction times and incur high costs. Sendit.Money asserts that this is because non-fiat currencies are changed multiple times before they are received. The company aims to change this. Its prototype application for African markets was received amidst positive feedback. It is now building a cost-effective mobile wallet providing a secure and inexpensive way to send and receive money that also allows users to compare transfer fees of different remittance agents in real-time. Sendit.Money was shortlisted as Best Global start-up at the 2020 Wales Startup Awards. The company will build and launch its Most Valuable Product (MVP) in Q3 of 2021. It will also use the funding to begin work with an authorised entity to become an approved representative.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £182,732
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £118,950
Wirex is a UK financial technology company that aims to bring crypto & fiat currencies together on one simple payments portal. The company is building a platform where buying, holding, saving and spending any digital and traditional currency is quick, easy and accessible. The Wirex app supports 12 fiat and 10 crypto currencies, operates in 130 countries, and has more than 3.1 million registered users. Wirex launched the first Visa crypto-enabled payments card in the world. It has a £3 billion cumulative transaction volume and plans to expand to the USA by end-2020. Wirex will use the investment to allow millions of its users to own a share of the brand.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £3,703,120
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
WhyBuy is a rental platform that allows a user to rent out items or entities he/she may want to another person. WhyBuy asserts that consumers want to be able to access items for brief periods, and the company aims to be the go-to provider in this segment. It endeavours to save time, space, money and the environment through its business model that is backed by a 100% electric delivery fleet. The company has tested its supply chain to ensure orders are placed despite COVID-19 restrictions. Its app has seen 8000+ downloads from mid-June to end-July 2020 at just over £3 per acquired download across the App Store and Google Playstore. It will use 75% of the investment for marketing, 5% to expand its electric fleet, and 15% as stock and overhead expenses.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £309,260
Wombat is an investment platform that encourages millenials in the UK, Europe and beyond to invest in some of the world’s best-known brands for as little as £10. Their mission is to empower the generation of millenials to manage, save and grow money by breaking down barriers to traditional investing. The Wombat app was launched in the summer of 2019, and the company has already acquired more than 5,000 customers. Moreover, the company was nominated as Best Newcomer for the Robo Investing Awards and received positive press coverage. With the proceeds, Wombat is planning to build a strong customer base, fulfil growth strategy with a significant increase in marketing, product development, and to educate customers about investing.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £435,717
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
AdLaunch is an online video maker tool aimed at social media advertising creation. Using its patented AI-powered video generation technology, it enables businesses to create multiple high-quality videos, realtime previews and edit videos in the browser itself. This helps companies undertake online video advertising almost instantaneously within their respective budgets. AdLaunch has 11,000 users in over 130 countries worldwide. It has made 1.4 million pre-licensed HD videos and high-quality photos. The company aims to become synonymous with creating data-driven video ads and video campaigns. AdLaunch was awarded the 'Third Prize' at the Slush 100 pitch competition out of 2650 companies. it also secured three government R&D grants totaling £219,000 from the Business Finland - the Finnish Innovation Agency. AdLaunch is partnering with AppSumo which has a user base of 730,000 registered newsletter readers. With the proceeds, the company will develop its video generator and invest £8000 per month on Google, Facebook, and YouTube advertising to accelerate its customer acquisition.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £85,278
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph